SEATTLE, Wash and VANCOUVER, British Columbia, April 22, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be hosting a Virtual Non-Deal Roadshow on Tuesday, April 27, 2021, at 9:00AM EDT. Achieve’s Chief Executive Officer, John Bencich, will be providing a corporate presentation and participating in a Q&A session with John Vandermosten, Senior Biotech Analyst at Zacks Small Cap Research.

To access the presentation, please visit

About Achieve and Cytisinicline 
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2

Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S. Achieve is currently enrolling smokers in the 750-subject, Phase 3 ORCA-2 study of cytisinicline at 16 sites in the U.S. For more information on cytisinicline and the ORCA-2 study, visit or

About Zacks Small Cap Research
Zacks Small Cap Research focuses on small and micro-cap companies that are under followed or under valued by Wall Street.  Our analysts seek to identify and report on these companies, bringing investors a unique opportunity to gain insight on small cap investments.  Zacks SCR’s goal is to produce high quality, institutional research for the small cap investor.

About SNN.Network
SNN.Network is your multimedia financial news platform for discovery, transparency, and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the mos